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Summary  1	  
Use of totally implantable venous access ports (TIVAP) is a standard clinical practice, in 2	  
particular for patients with solid cancers, hematologic malignancies and chronic digestive 3	  
diseases. Use of TIVAPs allows long-term administration of veinotoxic compounds, improves 4	  
patient quality of life and reduces risk of infection. However, microbial contamination, 5	  
formation of pathogenic biofilm in TIVAPs and subsequent infection are associated with 6	  
morbidity, mortality and increased healthcare costs. In case of TIVAP-related infection, local 7	  
and systemic complications, or infection related to specific pathogens may constitute 8	  
indications for device removal. Alternatively, conservative treatment can be proposed with 9	  
the combination of systemic antibiotics and antibiotic lock therapy. In light of recent in vitro 10	  
and in vivo fundamental or clinical research addressing epidemiology, diagnosis and 11	  
prevention of TIVAP-related infections, with a particular focus on antibiotic lock therapy, this 12	  
review presents current challenges and promising strategies to improve the management of 13	  
TIVAP-related infections even if some of them are still at an early developmental stage and 14	  
need clinical validation.  15	  
 16	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Search strategy and selection criteria  1	  
References for this review were identified through searches of PubMed for articles published 2	  
in English between January 1980 and July 2013 including totally implantable venous access 3	  
port (TIVAP)-related infections for any indication of TIVAP insertion. We restricted studies 4	  
by use of the terms: “Totally implantable venous access”, “Totally Implantable port”, “Port-a-5	  
cath”, "Catheters, Indwelling", “Central venous catheter”, “Port-a-cath infection”, “Port-6	  
pocket infection”, "Catheter-Related Infections", "Bloodstream infections", "Bacteremia" and 7	  
“Infection”. We focused on studies assessing TIVAP-related infections epidemiology, risk 8	  
factors, microbiology, diagnosis, prevention, treatment and prognosis. Regarding treatment, 9	  
we also included the following key-words: “Sepsis/prevention & control”, “Catheter-Related 10	  
Infections/drug therapy”, “Bacteremia/drug therapy”, “antibiotic lock therapy”, “ethanol 11	  
lock”, “antibiotic lock technique”, “antifungal lock therapy”. For epidemiologic or therapeutic 12	  
studies including different types of long-term intravascular catheters (LTIVC), we retained 13	  
them if specific data about TIVAP were described. Articles resulting from these searches and 14	  
relevant references cited in these articles were reviewed. 15	  
 16	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Introduction 1	  
Patients may require long-term administration of potentially veinotoxic compounds due to 2	  
chronic conditions such as solid tumors, hematologic malignancies, digestive diseases, cystic 3	  
fibrosis (CF) or infection with human immunodeficiency virus (HIV).1,2 Long-term 4	  
intravascular catheters (LTIVC) were developed to reduce the associated toxicity and risk of 5	  
bacterial or fungal colonization due to the subcutaneous route or “tunnel” that impedes the 6	  
migration of microorganisms present on the surface of the skin.3,4 In the early 80’s, an initial 7	  
report described the use of a new type of LTIVC called a totally implantable venous access 8	  
port (TIVAP).5 TIVAP is composed of a subcutaneously implanted port (or reservoir) 9	  
connected to a central venous catheter, most frequently inserted into the internal jugular, 10	  
subclavian or cephalic vein.2 Use of TIVAPs is now a standard clinical practice and has 11	  
significantly increased patients’ comfort and quality of life, as compared to other LTIVCs.2 12	  
TIVAPs are inserted for the administration of antineoplastic chemotherapy, parenteral 13	  
nutrition, blood products and for prolonged antimicrobial treatment in CF.2,6,7 The number of 14	  
implanted TIVAPs is increasing and more than 400,000 of them are sold each year in the 15	  
USA.8 Despite a reduction of the risk of microbial contamination due to total implantation 16	  
under the skin, 3 to 10% of TIVAP carriers experience a related infection which is the most 17	  
common indication for TIVAP removal, illustrating the impact of this complication on patient 18	  
care and the necessity for focused research in this area.9-14 19	  
This review aims to provide insights into challenges associated with TIVAP-related 20	  
infections, including diagnosis, prevention, and novel approaches that may improve patients’ 21	  
management.  22	  
 23	  24	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Epidemiology reflects risk factors and routes of colonization 1	  
Depending on the indication for TIVAP insertion, patients are exposed to different risk 2	  
factors and therefore exhibit different infection rates. For instance, if TIVAP is inserted for 3	  
antineoplastic chemotherapy or in CF patients, the incidence density of infection ranges from 4	  
0·11 to 0·37/1,000 catheter-days.6,9,10,13-17 In cancer patients, the risk of TIVAP-related 5	  
infection appears to remain unchanged with incidence densities of 0·21 and 0·20/1,000 6	  
catheter-days reported in 1993 and 2011, respectively.9,13  7	  
If TIVAP is used for total parenteral nutrition (TPN), incidence density of infection is higher 8	  
and is comprised between 0·33 and 3·2/1000 catheter-days with heterogeneous data 9	  
depending on the indication for TPN.7,18,19 In HIV-infected patients, incidence density ranges 10	  
from 1·5 to 3·81/1,000 catheter-days, probably because when a LTIVC is required, these 11	  
patients combine most of the risk factors of infection identified so far.20,21 The reported time 12	  
to infection from TIVAP insertion ranges from 80 to 192 days with extreme values of 2 and 13	  
1406 days.10,13,20,21 14	  
These discrepancies between patient groups probably reflect exposure towards different risk 15	  
factors and TIVAP handling frequency. Indeed, a prospective study demonstrated that the 16	  
frequency of LTIVC handling (including about 50% of TIVAP) was associated with infection 17	  
incidence.21 Additional risk factors are described in Panel 1. 18	  
Since frequency of TIVAP handling is one of the major risk factor identified, it is not 19	  
surprising to observe that coagulase-negative staphylococci (CoNS), which are frequent 20	  
colonizers of the human skin and mucosal flora, are one of the leading pathogens responsible 21	  
for TIVAP-related infections.22 For instance, among 29 cases of TIVAP-related infections, a 22	  
majority of infections (57%) were caused by CoNS, other microorganisms being Gram-23	  
negative rods (GNR) (20%), S. aureus (7%) and C. albicans (3%).13 More recent studies 24	  
described a higher rate of GNR (up to 40%) and yeasts (up to 23%).10,20,23 This shift may be 25	  
explained by different factors such as antineoplastic chemotherapy intensification with more 26	  
sustained neutropenia allowing translocation of microorganisms from the gut to bloodstream, 27	  
besides more frequent use of TPN and broad-spectrum antibiotics.10 To note, early TIVAP-28	  
related infections (≤30 days) are more frequently caused by S. aureus than late infections 29	  
(50% vs.12%, respectively).24 30	  
Regarding antibiotic resistance, a French cohort of cancer patients reported that 58% of CoNS 31	  
and 25% of S. aureus were methicillin-resistant (MR).24 MR is more frequent in the USA as 32	  
suggested by data reported by the National Healthcare Safety Network and also in a study of 33	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S. aureus catheter-related bloodstream infection (CRBSI) in cancer patients, with 37 to 55% 1	  
of S. aureus being MR.25,26  2	  
As TIVAPs are totally implanted, risk of extraluminal colonization is low and mostly occurs 3	  
during TIVAP insertion, resulting in surgical site infection. Once the device is inserted, 4	  
contamination may occur during repeated punctures with Huber needles, if the skin has not 5	  
been completely cleaned, therefore leading to an intraluminal colonization that can spread 6	  
from the port to the catheter tip.27-29 In case of BSI coming from another focus of infection, 7	  
bacteria may adhere on the catheter tip, therefore defining a hematogenous route of 8	  
colonization, which is rare except in case of S. aureus. After device contamination, bacteria 9	  
adhere to the internal or external surface of TIVAP, depending on the source of 10	  
contamination, using proteinaceous stalks called adhesins.30  11	  
Bacterial adhesion is influenced by the type of catheter material, bacterial characteristics or by 12	  
the presence of a layer of blood components. Indeed, once an indwelling device is inserted, a 13	  
conditioning film made of host components like fibrin or platelets covers it.27,31 These 14	  
deposits may enhance or inhibit bacterial adhesion besides reducing the efficacy of any 15	  
antibiotic-releasing surface. After several days, all catheters get covered by a fibrin sheath.32 16	  
Following adhesion, bacteria multiply and constitute a surface-associated microbial 17	  
community called a biofilm, which is embedded in a matrix of extracellular polymeric 18	  
substances produced by both bacteria and the host.11,30 Biofilm bacteria exhibit tolerance 19	  
defined as the ability to survive high concentrations of antibiotics.33 Thus, systemic 20	  
antibiotics can cure TIVAP-related BSI but the source of infection cannot be eradicated 21	  
unless the device is removed or intraluminal treatment used. This high tolerance is 22	  
responsible for infection relapse with the same pathogen. Preventive approaches are therefore 23	  
pivotal in order to avoid any microbial contamination and subsequent biofilm formation. 24	  
 25	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Preventive strategies to reduce risks of colonization 1	  
Because of a reduced risk of infection, TIVAPs are favored over other LTIVCs for use in 2	  
treatment of solid tumor and pediatric hematology patients.13,23,34 In case of prolonged TPN, 3	  
due to a higher risk of infection associated with TIVAPs, a tunnelled catheter may be 4	  
preferred if daily vascular access is required.1,7 If TIVAP is chosen in oncology or 5	  
hematology patients, it should be inserted as early as possible, due to increased risk of 6	  
infection in case of neutropenia.35,36 Then, preventive strategies must be applied during and 7	  
after TIVAP insertion. 8	  
 9	  
Preventive measures during TIVAP insertion 10	  
Trained personnel with maximum sterile barrier precautions, including sterile gloves, cap, 11	  
mask, sterile gown and a sterile full body drape, must perform TIVAP insertion.2,37,38 For skin 12	  
preparation, alcohol-based chlorhexidine or alcohol-based povidone-iodine should be used at 13	  
least 30 seconds and left to dry, as suggested by recent Infectious Diseases Society of 14	  
America (IDSA) guidelines.38 Chlorhexidine concentration should be >0·5% (usually 2% in 15	  
clinical trials) with alcohol. Although recommended in France, skin cleaning (or scrubbing) 16	  
before antiseptic application is still debated.39 Furthermore, no randomized, prospective 17	  
clinical trial has directly compared the two alcohol-based antiseptic solutions, therefore 18	  
advocating a comparative study.39 19	  
The choice of venipuncture site is not associated with different infection rates as 20	  
demonstrated by a prospective study of 403 patients randomly allocated to an internal jugular 21	  
vein or subclavian vein insertion, or a surgical cut-down through the cephalic vein.40 If the 22	  
superior vena cava is not accessible - for instance due to thrombosis - TIVAP can be inserted 23	  
in the femoral vein with an infection incidence of 0·69/1,000 catheter-days, as reported 24	  
among 20 cancer patients.41 Use of ultrasound guidance for catheter insertion has not been 25	  
shown to reduce the rate of TIVAP-related infections but significantly reduces the number of 26	  
attempts and increases patient comfort.40,42 Systemic antibiotic prophylaxis has no 27	  
demonstrated benefit during TIVAP insertion and is not indicated.43-45 28	  
 29	  
Preventive measures after TIVAP insertion 30	  
Training of patients, nursing teams and physicians is mandatory to minimize the risk of 31	  
bacterial contamination.7 The Huber needle used to access the TIVAP must be inserted by 32	  
trained nurses and requires that operators wear a facial mask, a cap and use sterile gloves. 33	  
Skin disinfection must be performed with an alcoholic antiseptic, prior to each needle 34	  
	   8	  
insertion (see above).38 The Huber needle can be changed every seven days if vascular access 1	  
is maintained continuously.10 During needle withdrawal, an experimental study suggested that 2	  
positive pressure using saline injection reduces the risk of blood reflux, therefore preventing 3	  
catheter tip occlusion.46 It is now recommended that heparin lock or flush after TIVAP use 4	  
should not be performed, as sterile saline locks are equally efficient to prevent functional or 5	  
infectious complications.38,47 Even if different studies demonstrated the benefits of 6	  
chlorhexidine-impregnated sponges or dressings for the prevention of CRBSI in intensive 7	  
care units, no studies including TIVAP have been published.  8	  
 9	  
Lock solutions and coatings to prevent TIVAP-related infections 10	  
The principle of preventive antibiotic lock therapy (ALT) is to inject highly concentrated 11	  
antibiotic solution inside the TIVAP lumen. This solution dwells for extended time periods in 12	  
order to eradicate any bacteria that might get injected inside TIVAP due to incomplete skin 13	  
antisepsis. Preventive ALT can thus only prevent intraluminal contamination. The chosen 14	  
volume must allow coverage of the whole internal surface and therefore depends on the type 15	  
of device. A meta-analysis demonstrated that ALT or antibiotic flush made of vancomycin 16	  
reduced the risk of CRBSI.48 Other groups have assessed the combination of antibiotic 17	  
(minocycline) and a chelator such as ethylene diamine tetra-acetic acid (EDTA).49 Two 18	  
studies in the pediatric oncology setting have shown that minocyline-EDTA ALT was more 19	  
effective than heparin for the prevention of CRBSI.50,51 Nevertheless, systematic use of ALT 20	  
could lead to increased antibiotic resistance.31,52 Thus, recent IDSA guidelines recommend to 21	  
restrict the use of preventive ALT to patients with LTIVC who experienced multiple CRBSI 22	  
despite optimal aseptic techniques.38  23	  
Limited data are available for non-antibiotic lock solutions, such as ethanol- or taurolidine-24	  
locks. One preliminary pediatric study using ethanol locks including 12 patients with TIVAP 25	  
was interrupted as 3 patients experienced TIVAP occlusion.53 A meta-analysis showed that 26	  
ethanol lock therapy reduces the incidence of CRBSI in pediatric TPN with tunnelled 27	  
catheters but increases the risk of thrombosis.54 Therefore, ethanol lock could be proposed in 28	  
cases of high-risk TPN patients with tunnelled catheters.55 Mild and self-limited adverse 29	  
effects have been reported, especially after flushing the lock, such as dizziness, nausea, 30	  
headaches, facial flushing and, eventually, an alcohol taste in the mouth.56,57  31	  
Taurolidine, a derivative from of the amino acid taurine, was proposed as a lock therapy in 32	  
1993 because of its antimicrobial effect against a broad range of microorganisms in vitro.58-60 33	  
Although studies conducted in hemodialysis patients are encouraging, data supporting its use 34	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as a lock in TIVAP are limited.61,62 In pediatric cancer patients, an initial study showed no 1	  
significant reduction of CRBSI with taurolidine/citrate as compared to heparin, with ~75% of 2	  
TIVAP patients amongst LTIVC.63 A more recent study in pediatric hematology patients 3	  
showed a significant reduction of CRBSI with taurolidine/citrate as compared to heparin but 4	  
included only tunnelled catheters.59 A randomized study in TPN patients demonstrated that 5	  
taurolidine/citrate reduced the rate of CRBSI when initiated after the first episode of 6	  
infection, as compared with heparin (TIVAP represented ~ 40% of LTIVC).64 Based on these 7	  
results, larger comparative studies with TIVAP are needed to define the precise role and 8	  
indications of ethanol or taurolidine as preventive locks. 9	  
The use of CVC coatings has been extensively studied in case of short-term CVC, leading to a 10	  
significant reduction of the risk of CRBSI.65,66 As LTIVCs dwell for a longer time in the 11	  
blood flow, the formation of the conditioning film reduces the antimicrobial action of the 12	  
coating.27 Furthermore, in case of antibiotic-releasing surfaces, the effect will stop once the 13	  
device is exhausted. A single study assessed LTIVC coated with minocycline/rifampin but 14	  
with a relatively short catheterization time period (mean duration of 66±31 days) and reported 15	  
a significant reduction of CRBSI.67 Clinically significant drug delivery was maintained at 16	  
least 35 days post catheter insertion. Thus, developing an efficient surface modification or 17	  
antibiotic coating that would help preventing colonization is still a major challenge (see 18	  
“Future Treatments” section). 19	  
 20	  
 21	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Diagnosis of TIVAP-related infections 1	  
TIVAP-related infection is easily suspected if the patient exhibits local signs such as pain or 2	  
erythema at the site of TIVAP implantation. However, diagnosis is more difficult in case of 3	  
isolated fever, chills or severe sepsis. Recent IDSA guidelines have proposed three classes of 4	  
TIVAP-related infections:68 5	  
-Local complicated infections, defined as a tunnel or port-pocket infection with extended 6	  
erythema or induration (more than two cm), purulent collection, skin necrosis and 7	  
spontaneous rupture and drainage (Figure 1A).68  8	  
-TIVAP-related BSI, defined as a positive blood culture drawn from a peripheral vein 9	  
associated with evidence that the BSI originates from the TIVAP using paired blood cultures 10	  
or culture of a component of the removed TIVAP (see below). TIVAP-related BSI can 11	  
therefore be defined with or without device removal.68  12	  
-Catheter-related infection, defined by the association of local or general signs of infection 13	  
and a positive culture of the catheter tip.68 14	  
Based on these criteria, a diagnostic algorithm including clinical signs and microbiological 15	  
workup can be proposed (Figure 2).  16	  
 17	  
Diagnosis of local infection 18	  
Clinical signs of local infection such as erythema or purulent exudate at the site of TIVAP 19	  
implantation has high specificity, but little sensitivity for the diagnosis of TIVAP-related 20	  
infection.68 Indeed, local signs are reported in only 7 to 12% of TIVAP-related BSI and as 21	  
local infections are caused by extraluminal contamination, they can occur without any 22	  
concomitant BSI.24,69,70 Erythema can also be caused by non-infectious factors such as 23	  
allergy. To confirm local infection, a positive culture of aseptically removed material 24	  
surrounding the port such as purulent fluid, skin necrosis or swabbing of the port surface is 25	  
mandatory.24,71 Peripheral blood cultures should also be performed to rule out an associated 26	  
BSI (Figure 2). 27	  
 28	  
Diagnosis of TIVAP-related BSI without device removal  29	  
This diagnosis relies on the identification of the same microorganism in paired blood 30	  
cultures.68 Correct interpretation of the test requires blood samples to be performed 31	  
consecutively, with the same volume of blood drawn from a peripheral vein and from the 32	  
TIVAP through a Huber needle, ideally before the initiation of antimicrobials.68,72,73 Another 33	  
critical point is to precisely label the origin of each blood culture bottle.68 The two most 34	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commonly used methods for diagnosing CRBSI are simultaneous quantitative blood cultures 1	  
and the differential time to positivity (DTP) of qualitative blood cultures.72,74-76 If TIVAP is 2	  
the source of BSI, the inoculum will be higher in the blood drawn from TIVAP, as compared 3	  
with peripheral vein, therefore leading to a shorter time to positivity (difference ≥ two hours) 4	  
or a higher bacterial quantification (≥four-fold).68,72,73,75,76 When used for the diagnosis of 5	  
LTIVC-related BSI, these two methods have sensitivity above 90% and specificity close to 6	  
100% and between 75% and 91% for quantitative paired blood cultures and DTP, 7	  
respectively.72,75,76 They are nevertheless considered equivalent in recent guidelines and the 8	  
choice of a technique will mostly rely on local equipment and training.68  9	  
To reduce the risk of contamination when blood is drawn from TIVAP, a rigorous skin 10	  
disinfection is mandatory before sampling (see “Prevention” section).68 11	  
 12	  
Diagnosis of TIVAP-related BSI after device removal  13	  
The demonstration that a BSI originates from a TIVAP relies on the identification of the same 14	  
microorganism in a TIVAP component and peripheral blood cultures. The catheter tip (four-15	  
cm distal part) can be cultured using the semiquantitative or quantitative methods with 16	  
thresholds defining a significant colonization of >15 CFU and ≥103 CFU/mL, respectively 17	  
(Figures 3A and B).77,78 Both methods can be equally used but are associated with sensitivity 18	  
below 50% for the diagnosis of TIVAP colonization, stressing the importance of using other 19	  
techniques.68,69,71,79 For instance, it has been proposed to perform quantitative culture of the 20	  
TIVAP septum using an adapted Brun-Buisson method (Figures 3A and C).69 With a 21	  
threshold of 103 CFU/mL, this method was associated with 93% sensitivity and 100% 22	  
specificity for the diagnosis of TIVAP-related BSI.69 Furthermore, after septum removal, if 23	  
macroscopic debris or clots are present, they can be sampled and cultured with a sensitivity 24	  
and specificity of 100% in case of TIVAP-related BSI.71 The main limitations of port septum 25	  
and port deposit cultures are lack of technical standardization and absence of a consensus 26	  
threshold.68. Therefore, performing both catheter tip culture and a culture of a component of 27	  
the port reservoir is advisable.68 Careful handling of explanted materials will reduce the risk 28	  
of contamination in the clinical microbiology laboratory. 29	  
 30	  
Diagnosis of fungal TIVAP-related BSI 31	  
Without TIVAP removal, such a diagnosis is challenging as studies assessing paired blood 32	  
cultures infrequently included study of fungal infections72,74,75,80 Some authors have proposed 33	  
to use the time taken to detect Candida spp. growth in peripheral blood as a diagnostic tool, 34	  
	   12	  
since time to positivity is shorter in case of catheter-related (CR) candidemia (17±2h) than 1	  
candidemia from another source (38±3h).81 The objective of this approach would be to rule 2	  
out the catheter as the source of candidemia if time to positivity is above 30 hours. In case of 3	  
TIVAP removal, microbiological methods and thresholds are the same, and culture on blood 4	  
agar is sensitive enough for the growth of fungi involved in TIVAP-related infections, even if 5	  
they may require a longer incubation time than bacteria (24-72h).82 6	  
 7	  
Workup to rule out complications 8	  
When TIVAP-related BSI is suspected, clinicians should look for infectious complications 9	  
such as severe sepsis, endocarditis, or other hematogenous complications (Figures 1B, C and 10	  
D).24 Recent guidelines recommend systematic transesophageal echocardiography in case of 11	  
S. aureus TIVAP-related BSI.68 Nevertheless, it is very likely that in selected patients without 12	  
intracardiac devices and with rapid clearance of BSI, a transthoracic echocardiography 13	  
performed at least 5 days after BSI onset can safely rule out infective endocarditis.83-87 In case 14	  
of clinical signs of thrombophlebitis or persistent BSI despite appropriate systemic 15	  
antimicrobial therapy, venous ultrasonographic examination should be performed, especially 16	  
in case of S. aureus TIVAP-related BSI (Figure 1B).68,88 17	  
Whatever the microorganism, persistent BSI after 3 days of adequate antimicrobials should 18	  
prompt a complete workup including echocardiography and, venous ultrasonographic 19	  
examination with or without a computed tomography (CT)-scan.68 20	  21	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Treatment: should TIVAP be removed or retained? 1	  
In the case of CRBSI, the treatment of choice is systemic antimicrobial therapy in conjunction 2	  
with removal of the colonized device.4 However, in case of TIVAPs, reduced venous access, 3	  
potential presence of coagulation disorders, the need for a new procedure and its cost, all 4	  
argue in favor of attempting a catheter salvage, if the clinical situation allows it.68  5	  
TIVAP removal is mandatory, regardless of the microbial etiology, in case of complicated 6	  
TIVAP-related infection defined by tunnel or port-pocket infections, severe sepsis or septic 7	  
shock, endocarditis, septic thrombophlebitis, osteomyelitis or other hematogenous seeding, as 8	  
suggested by IDSA guidelines (Figure 1 and 4).68 Furthermore, infections caused by S. aureus 9	  
or Candida spp. warrant TIVAP removal, except in exceptional circumstances (see below) 10	  
(Figure 4).68,89 If a conservative strategy is decided upon, the TIVAP should be removed in 11	  
case of persistent positive blood cultures 72 hours after the initiation of antibiotics.68  12	  
In case of uncomplicated TIVAP-related BSI not caused by S. aureus or Candida spp., a 13	  
conservative treatment using a combination of systemic antimicrobials and ALT can be 14	  
considered.68 Indeed, as most of LTIVC-related infections are associated with intraluminal 15	  
colonization, instillation of high concentrations of antimicrobial solution filling the entire 16	  
volume of the lumen and dwelling for an extended period of time may allow sterilization of 17	  
the device.90-92 Despite several limitations, there is a growing body of evidence favoring the 18	  
use of ALT. For instance, a randomized, placebo-controlled study showed that ALT plus 19	  
systemic antimicrobial therapy is more effective than systemic antimicrobial therapy alone for 20	  
treating LTIVC-related BSI, although not reaching statistical significance due to the small 21	  
sample size.70 In addition, large uncontrolled studies demonstrated high cure rates in patients 22	  
with uncomplicated LTIVC-related BSI due to CoNS (89%) or GNR (95%) (Table 1).89,91,93  23	  
 24	  
How to perform ALT? 25	  
No clinical trials have compared one drug to another and some in vitro studies have given 26	  
conflicting results with mitigated clinical relevance.94,95 As described in Table 1, more 27	  
frequently used antibiotics are glycopeptides, aminoglycosides or fluoroquinolones and their 28	  
use has been associated with high rates of therapeutic success. The chosen antibiotic must be 29	  
active in vitro against the identified microorganism. Ideally, antimicrobials should be 30	  
administered at a concentration at least 1000-fold above the minimal inhibitory concentration 31	  
(MIC) (frequently between 1 and 5 mg/mL) with a volume that fills the entire TIVAP lumen. 32	  
In most studies, ALT is prescribed for 10 to 14 days (Table 1) and the lock solution is usually 33	  
replaced every 12 to 24 hours, depending on the necessity for vascular access.68 Replacing the 34	  
	   14	  
solution every 48 or 72 hours has also been performed safely.93 In case of TIVAP-related BSI, 1	  
systemic antimicrobials should always be administered for 10 to 14 days.68 Addition of 2	  
heparin in ALT has been proposed to avoid thrombosis of the catheter but no comparative 3	  
data support its use and adverse effects have been reported such as bleeding or the 4	  
enhancement of S. aureus biofilm formation in vitro.96,97 Therefore, ALT can be performed in 5	  
saline or heparin, at 10 to 100 IU/mL (Table 1).68 In case of conservative treatment, close 6	  
follow-up is mandatory to detect treatment failure and includes, at least, blood cultures 7	  
performed 3 days after the beginning of the treatment and 2-4 weeks after the end of the 8	  
treatment (Figure 4).  9	  
 10	  
Adapting treatment to the identified microorganism (Figure 4) 11	  
In case of uncomplicated CoNS infection, the cure rate of ALT is high (>80%), and failures 12	  
are mainly due to relapses during the first month of follow-up.89,91 In case of treatment failure 13	  
or recurrence of infection, TIVAP removal should be considered. Glycopeptides for 10 to 14 14	  
days have been extensively used and a prospective uncontrolled study identified a trend 15	  
toward a higher success rate with teicoplanin as compared to vancomycin.89,91 Additionally, 16	  
daptomycin can be considered as a possible alternative (see below).94,95  17	  
Conservative treatment of GNR TIVAP-related BSI is associated with a cure rate between 18	  
87% and 95%, when local or distant complications are excluded.89,93 Although recent 19	  
guidelines suggest TIVAP removal in the case of P. aeruginosa infection, Pseudomonas spp. 20	  
have also been included in clinical ALT studies, with the same success rates as 21	  
Enterobacteriaceae. Fluoroquinolones and aminoglycosides are the antimicrobials most 22	  
commonly used for these infections.89,93  23	  
S. aureus TIVAP-related BSI should lead to catheter removal due to the high failure rates of 24	  
ALT (45% to 60%), with some cases of related mortality.89,98 ALT can nevertheless be 25	  
considered in exceptional circumstances after having excluded local or distant complications, 26	  
such as infective endocarditis with transesophageal echocardiography.68 Cefazolin and 27	  
vancomycin are the antimicrobials most frequently used in this setting and the efficacy of 28	  
other antimicrobials such as aminoglycosides or daptomycin should be evaluated in clinical 29	  
studies.89,95,98,99  30	  
Infections due to Candida spp. should lead to catheter removal, and conservative treatment 31	  
should only be considered in limited situations after ruling out local or distant complications 32	  
(see below). Although optimal antifungal-lock therapy has not been established in this 33	  
unusual situation, amphotericin B (liposomal or deoxycholate) and ethanol are the most 34	  
	   15	  
commonly used compounds.100 In case of catheter retention, a systemic antifungal with 1	  
activity against Candida biofilms should be favored such as lipid-based amphotericin B or 2	  
echinocandins (see Panel 2).101  3	  
In case of polymicrobial infections, ALT can be proposed if two criteria are met: i) none of 4	  
the involved microorganisms is S. aureus or Candida spp. and ii) a single antimicrobial can 5	  
be used to treat them all or a stable association of antimicrobials can be used.93,102 6	  
 7	  
Recently developed locks 8	  
Aside from commonly used antimicrobials in ALT, 70% ethanol and daptomycin have been 9	  
more recently used as ALT for conservative treatment. Regarding ethanol, no comparative 10	  
studies have been published and most uncontrolled studies have been conducted in pediatric 11	  
patients, with a less accurate diagnosis due to lack of peripheral blood cultures.103-105 For 12	  
instance, a retrospective study of 51 patients treated with 70% ethanol dwelling for five days 13	  
reported a cure rate of 100% but recurrences in 10% of cases.105 More recently, daptomycin 14	  
has been proposed as lock therapy because of its potent in vitro effect against biofilms.106,107 15	  
A phase II clinical study was conducted using daptomycin ALT in 13 patients with LTIVC-16	  
related infections caused by CoNS or E. faecalis, half of them occurring on TIVAP.94 After a 17	  
mean of 14 days of treatment, cure rate was 85% (11/13 patients).94 Comparative clinical 18	  
studies are now expected to determine if ethanol or daptomycin are more efficient or more 19	  
quickly effective than already used antibiotics.  20	  
 21	  22	  
	   16	  
Future treatments and needs 1	  
Considering limitations of currently proposed diagnostic, preventive or therapeutic measures, 2	  
many questions still need to be addressed in the field of TIVAP-related infections. 3	  
 4	  
Improving diagnosis 5	  
Despite their help in diagnosing TIVAP-related BSI without device removal, paired blood 6	  
cultures are not foolproof as both methods give false-positive and false-negative 7	  
results.69,73,80,108,109 Therefore, different investigators have tried to develop molecular biology 8	  
tools for the diagnosis of TIVAP-related infections. For example, amplification and 9	  
sequencing of bacterial DNA (16S ribosomal RNA gene) has been performed on blood drawn 10	  
from CVCs in cases of CRBSI or after TIVAP removal, on port sonication fluid and biofilms 11	  
from the internal surface of the port.110,111 Whereas these methods are more sensitive than 12	  
cultures in case of previous antibiotic administration, their reduced specificity of ~80% due to 13	  
false-positive results (external DNA contamination during procedure) leads to other 14	  
diagnostic challenges. Other groups have tried to identify biomarkers of biofilm formation 15	  
inside the port that would allow an earlier diagnosis of colonization before the onset of BSI. 16	  
For instance, certain LPS modifications are only occurring within Gram-negative bacterial 17	  
biofilms.112  18	  
Regarding fungal infections, the use of selective blood culture bottles, polymerase chain 19	  
reaction or antigen detection on blood samples could allow faster and/or more sensitive 20	  
diagnosis but these methods still need to be assessed in the setting of TIVAP.113,114 21	  
 22	  
Prevention 23	  
Improvement of hygiene measures should always be attempted through definition and 24	  
implementation of local clinical bundles for TIVAP insertion and handling.4,38,68 Dedicated 25	  
infusion therapy teams could be involved in the education of healthcare workers and patients.4 26	  
Other preventive strategies are limited by the long-term implantation of TIVAP leading to 27	  
coverage by host blood components of any modified surface, and reduction of the effect of 28	  
antibiotic-coated catheters over time. One possible solution would be to use anti-adhesive 29	  
compounds inhibiting the deposition of blood components or inhibiting local thrombosis that 30	  
would delay or reduce the risk of formation of the protein film. For instance, a surface 31	  
modification using nonleaching polymeric sulfobetaine (polySB) is associated with a 32	  
significant reduction of adherence and activation of platelets and white blood cells.115 This 33	  
scaffold retains water on the catheter surface and not only reduces proteins, host cells and 34	  
	   17	  
microbial adhesion but also thrombus formation in vitro and in vivo.115 Although this and 1	  
other approaches provided encouraging results, they need to be assessed in long-term 2	  
settings.116 3	  
  4	  
Biofilm eradication inside TIVAP 5	  
Currently used antibiotics as lock therapy have drawbacks, such as possible treatment failure 6	  
or a long treatment duration.68 Several investigators have attempted to develop more efficient 7	  
and faster ALT to face these challenges. In vitro and in vivo studies identified several 8	  
potential lock candidates and, for instance, ethanol or daptomycin are now being clinically 9	  
assessed.94,103 Another approach is to use an adjuvant to increase antibiotic efficiency against 10	  
biofilms. For example, the association of an antibiotic and a chelator such as EDTA or citrate 11	  
has been proposed, since divalent cations play a key-role in maintaining biofilm matrix 12	  
stability.117 Addition of chelators destabilize the matrix and therefore increase antimicrobial 13	  
activity.118 Many in vitro studies have reported an antibiofilm effect of EDTA alone and a 14	  
synergistic effect when combined with gentamicin or minocycline/25% ethanol.119,120 In vivo, 15	  
the combination of gentamicin and EDTA led to complete eradication of biofilms of Gram-16	  
positive as well as Gram-negative bacteria formed inside TIVAP implanted in rats, therefore 17	  
paving the way to clinical studies.121 18	  
Fundamental research also led to the identification of compounds exhibiting promising 19	  
effects. Even though none of them have been assessed as ALT per se, their effect should be 20	  
examined in this perspective: 21	  
It has been demonstrated that the association of an aminoglycoside and a sugar such as 22	  
mannitol or fructose could increase antibiotic uptake in the most tolerant bacteria inside 23	  
biofilms called persister cells. Killing of persisters may lead to a more efficient treatment of 24	  
in vivo biofilms.122 Such an approach could easily be converted to an ALT composed of an 25	  
aminoglycoside plus sugar. 26	  
As quorum sensing (QS) is a key component of biofilm communication, many investigators 27	  
have speculated that interfering with QS signals might alter biofilm maturation thereby 28	  
leading to easier eradication. For instance, RNAIII inhibiting peptide (RIP), a compound 29	  
interfering with S. aureus QS efficiently prevented CVC-related infection in vivo.123 30	  
Another approach would be to favor bacterial biofilm dispersion as biofilm bacteria lose most 31	  
of their antibiotic tolerance when they return to a planktonic state.33 However, the dispersal 32	  
approach needs to be associated with systemic and local antibiotics as released bacteria from 33	  
the biofilm into the bloodstream may express virulence genes and lead to severe sepsis.124 34	  
	   18	  
Many compounds such as dispersin B, DNase I or autoinducing peptides have been described 1	  
to favor biofilm dispersion in vitro, and to a lesser extent in vivo.125,126  2	  
Many other compounds or strategies are currently being investigated and developed such as 3	  
vaccination, bacteriophages or association of antibiotics with non antibiotic compounds 4	  
through the screening of chemical libraries, but substantial research is still required before 5	  
reaching clinical studies.31,127-130 6	  
 7	  8	  
	   19	  
Conclusion 1	  
Thirty years of intense study of TIVAP-related infection epidemiology has led to an improved 2	  
delineation of patients at risk of infection, which is of key importance with regard to the 3	  
increasing number of inserted TIVAPs. Although ALT has proven to be a pivotal strategy for 4	  
the conservative treatment of selected uncomplicated TIVAP-related BSI, there is still much 5	  
work to be done, especially in light of recent experimental progresses made on reduction of 6	  
antimicrobial tolerance in TIVAP-associated infections using combinations of antibiotics and 7	  
antibiofilm compounds. It is also to be foreseen that preventive approaches will benefit from 8	  
device development specifically conceived to reduce microbial colonization and infection, for 9	  
instance using surface modifications with anti-adhesion properties. Finally, while the 10	  
diagnosis of TIVAP infections remains challenging, there are indications that infection and 11	  
biofilm biomarkers could be developed in a near future to assist clinicians in taking 12	  
appropriate preventive or curative decisions at early stages of TIVAP colonization. Such 13	  
timely therapeutic actions could significantly reduce the rate of device removal and 14	  
fundamentally change our current view of TIVAP management. 15	  16	  
	   20	  
Panel 1. Risk factors of TIVAP-related infections. When available, odd-ratios (OR) are 1	  
expressed with 95% confidence interval [95% CI]. 2	  
 3	  
Modifiable risk factors 4	  
-Frequency of TIVAP handling with an OR of 1·15 [1·03-1·3] for each 10% increase of the 5	  
frequency of LTIVC handling, especially among HIV-infected patients.21  6	  
-Use of total parenteral nutrition, because of a more frequent access to TIVAP, and because of 7	  
fluids such as lipid products that can increase microbial growth.7 OR=28·5 [4·2-200].131  8	  
-Difficulties during insertion (i.e. when several punctures are required) through formation of 9	  
local thrombus or hematoma that increase the risk of bacterial colonization. OR=25·6 [4·2-10	  
106].131 11	  
 12	  
Non-modifiable risk factors 13	  
-Age with a threshold depending on each study. <7 year-old;13 < 10 year-old (OR=18·4 [1·9-14	  
106·7]);131 < 40 year-old.10 15	  
-Chemotherapy for hematologic malignancies rather than solid tumors.13,132 OR=5·1 [1·5-16	  
17·5].133 17	  
-Hematopoietic stem cell transplantation, OR=1·74 [1·1-2·4].23 18	  
-Reduced autonomy, as expressed by a Karnofsky performance status ≤ 80%, in cancer 19	  
patients, OR=5·3 [1·5-19·3].21 20	  
-Presence of metastases in cancer patients, OR=4·1 [0·9-19·5].21  21	  
-Bacterial infection within the prior month, OR=2·1 [1·1-3·8] in HIV-infected patients and 22	  
OR=5·4 [1·2-25·3] in cancer patients.21 23	  
-Neutropenia among HIV-infected patients, OR=1·8 [1·1-3·1]21 and patients with 24	  
hematological malignancies, OR=15·1 [2·6-86·5].36  25	  
-Diabetes in CF-patients.6 26	  
 27	  
To note, no study identified a specific class of antineoplastic chemotherapy or radiation 28	  
therapy as being risk factors of TIVAP-related infection. 29	  30	  
	   21	  
Panel 2. Future challenges regarding TIVAP and candidemia. 1	  
All published international guidelines so far strongly recommend the early removal of any 2	  
central venous catheter (CVC) in case of candidemia whether or not it is catheter-related 3	  
(CR).68,101,134 Two situations should be distinguished. On one hand, if the candidemia is not 4	  
CR, it is plausible that catheter retention does not influence outcome, especially if an 5	  
antifungal efficient against Candida biofilms is used.135 A comparative study is needed to 6	  
definitively answer this question. On the other hand, if the candidemia is CR, it is very likely 7	  
that catheter removal is required. For instance, a retrospective study including 404 patients 8	  
with cancer, CVC and candidemia identified after multivariate analysis that early catheter 9	  
removal improved response to antifungal therapy only among patients with CR 10	  
candidemia.136 In this context, one major issue is that the diagnosis of fungal CRBSI without 11	  
catheter removal is still challenging due to poor clinical evaluation of paired blood cultures in 12	  
this setting.72,74,75  13	  
In case of CR candidemia, even if catheter removal is recommended, many patients cannot 14	  
afford a CVC replacement because of their general condition. Therefore, antifungal lock 15	  
therapy has been proposed to increase the likelihood of biofilm eradication, based on the same 16	  
principles as ALT.100 In vitro and in vivo studies reveal that against Candida biofilms: i) 17	  
azoles have poor activity; ii) lipid formulations of amphotericin B are more effective than 18	  
amphotericin B deoxycholate; and iii) echinocandins have excellent in vitro activity.100 Non-19	  
antifungal lock therapy against Candida biofilms have also been proposed such as EDTA in 20	  
combination with antifungals or minocycline, ethanol, heparin and even highly concentrated 21	  
antibiotics like doxycyline.100,137-140 Even if no comparative study is available, more than 20 22	  
patients were treated with various types of antifungal locks with an overall success rate of 23	  
77% with a publication bias that should be taken into account.100 Hence, ethanol lock therapy 24	  
could be a promising candidate with eight successes among ten reported patients.139,140 Of 25	  
note, most of these published cases are of pediatric patients with the limitation of diagnostic 26	  
criteria, frequently based on blood cultures drawn from the CVC without any peripheral blood 27	  
culture. Studies of antifungal lock therapy specifically for TIVAP-associated fungal infections 28	  
are clearly needed. 29	  
 30	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Figure 1. Totally implantable venous access port (TIVAP)-related infections may lead to 
local and hematogenous complications. A. Port-pocket infection (surrounded by black 
dashed line) and tunnel infection (white arrowhead) caused by S. aureus. B. Thrombophlebitis 
after TIVAP-related bloodstream infection (BSI) caused by S. aureus. Thrombus (black 
arrowhead) developed at the junction of internal jugular vein (black arrow) and subclavian 
vein (black star). C. Right pulmonary abscess (white arrow) with cavitation secondary to a S. 
aureus TIVAP-related BSI. D. C5-C6 spondylitis caused by S. lugdunensis after an episode of 
TIVAP-related BSI. Sagital view of cervical spine T2-weighted magnetic resonance imaging 
showing disc space narrowing (white arrowhead) and vertebral edema (white stars). Picture A 
kindly provided by Chantal Dreyer, Hôpital Beaujon, Clichy, France. All clinical photographs 
are from patients included in a previously published study.24 
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Figure 2. Diagnostic algorithm in case of suspicion of totally implantable venous access 
port (TIVAP)-related infection. ALT=antibiotic lock therapy. BC=blood cultures. 
BSI=bloodstream infection. DTP=differential time to positivity. QPBC=quantitative paired 
blood cultures. *Using quantitative or semi-quantitative method, see text and Figure 3.4,68  
† Difference between TIVAP colonization and probable TIVAP-related infection is made by 
the presence of clinical signs of sepsis and requires ruling out another focus of infection.  
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Figure 3. Microbiological methods for the diagnosis of totally implantable venous access 
port (TIVAP) colonization. A. Schematic view of a removed TIVAP. Samples should be 
transferred in sterile tubes and sent to the clinical microbiology laboratory (CML) right away 
or stored overnight at +4°C. Catheter tip (black star) is cut and the septum (white star) 
removed using sterile blade.68,69,141 Biological safety cabinets can be used. B. Culture of the 
catheter tip can be performed using the semiquantitative (Maki) or the quantitative (Brun-
Buisson) method.77,78 C. After removal, the septum is immersed in saline, vortexed or 
sonicated for CFU counting.69,141 D. In CML not permitted to use cutting blades, sterile saline 
(0.2mL) can be injected inside the reservoir then aspirated and plated.24 Swabbing of the 
internal surface of the port after septum removal is also proposed.111,142 As demonstrated for 
cardiac devices, incubating the explanted parts of TIVAP in broth for 48h without sonication 
or vortexing could be an option but needs to be validated.143 
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Figure 4. Treatment of totally implantable venous access port (TIVAP)-related 
bloodstream infection (BSI), according to IDSA guidelines.68 AB=antibiotic. 
AF=antifungal. ALT=antibiotic lock therapy. BC=blood cultures. IE=infective endocarditis. 
*In case of tunnel or port-pocket infection without BSI, TIVAP removal is also required with 
five to seven days of systemic antimicrobials.4,68,134  
† In case of P. aeruginosa TIVAP-related BSI, IDSA guidelines suggest that TIVAP removal 
is the first-line option.68 ‡ In 2009 IDSA guidelines, only ophthalmological examination is 
recommended for all patients although some clinicians also propose echocardiography and 
CT-scan.134 ¶ The source of the blood to be drawn is debated and some authors perform BC 
only from a peripheral vein or from TIVAP.102 To note, some authors consider that the 
presence of intracardiac or intravascular devices should preclude the use of ALT, even if this 
situation is not mentionned in IDSA guidelines.68 
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Table 1. Published studies on antibiotic or ethanol lock therapy for the conservative treatment of bacterial totally implantable venous access port 
(TIVAP)-related bloodstream infections (BSI) identified with the criteria described in the “search strategy” panel. Of note, most published 
studies excluded patients with complicated TIVAP-related BSI or infections caused by S. aureus or Candida spp. 
Clinical 
studies, year-
reference 
No of 
episodes 
treated 
with ALT 
Type of 
catheter† 
Micro 
organisms‡ Catheter use 
Systemic 
antimicrobial 
treatment, n 
(%) 
ALT or ELT (drug and concentration 
in mg/mL) 
Association 
with 
heparin*, 
IU/mL 
No of days 
of locks 
Cure rate, n 
(%) Success criteria 
1999-Domingo 
P. et al.144 27 100-0-0 57-3-3-6-30 
Antiinfectious CT 
in AIDS patients 9 (33) VAN (1), AMK (1) No 5 22 (81) 
Clinical + negative paired 
BC at the end of ALT 
1999-Piketty 
C. et al.145 31 100-0-0 100-0-0-0-0 
Antiinfectious CT 
in AIDS patients 31 (100) VAN (40), AMK (60) Yes, ND 3 [1-5] 13 (42) 
Clinical. No systematic 
BC  
2001-Longuet 
P. et al.141 16 100-0-0 41-24-0-12-23 
Antiinfectious or 
antineoplastic CT  16 (100) VAN (5) or TEC (5) +/- AMK (ND) No 8 [3-15] 7 (44) 
Clinical + negative paired 
BC 2-7 days after the end 
of ALT 
2002-Santarpia 
L. et al.7 60 86-14-0 67-15-0-6-12 TPN 60 (100) 
TEC (33-100), PIP (166-500), NET 
(50-150) or CLI (100-300) Yes, ND 7 50 (83) Undefined 
2002-Reimund 
J.M. et al.146 25 64-36-0 61-24-0-12-3 TPN 39 (100) VAN (1), AMK (1.5) or MIN (0.2) No ND 
25% if 
TIVAP-
50% if 
tunnelled 
Undefined 
2003-Viale P. 
et al.147 30 37-40-23 35-9-9-28-22 
Antiinfectious or 
antineoplastic CT, 
TPN 
15 (50) VAN (20), TEC (20), AMK (10), IMP (ND) No 14 28 (93) 
Clinical + negative paired 
BC 14 and 28 days after 
the beginning of ALT 
2004-
Koldehoff M. 
et al.148 
11 100-0-0 46-8-8-8-30 Antineoplastic CT  11 (100) Taurolidine (5) No 1 [1-3] 11 (100) § Undefined 
2005-Rijnders 
B.J. et al.70 22 91-9-0 63-14-0-0-23 
Mostly 
antineoplastic CT 22 (100) VAN (0.5) or CAZ (0.5) Yes, 100 11 [7-14] 14 (67) 
Clinical. No systematic 
BC 
2006-Fortún J. 
et al.149  19 74-26-0 74-0-10-16-0 
Antineoplastic CT 
and TPN  19 (100) VAN (2), GEN (2) or CIP (2) Yes, 20 12 [5-14] 16 (84) 
Clinical + negative 
catheter BC 2-5 days 
after the end of ALT 
2006-
Fernàndez-
Hidalgo N. et 
al.89 
115 16-73-11 49-18-5-16-12 Antineoplastic CT, TPN, hemodialysis  115 (100) VAN (2), AMK (2) or CIP (2) Yes, 20 12 [8-14] 94 (82) 
Clinical + negative BC 1 
month after the end of 
ALT 
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2006-Onland 
W. et al.105 51 21-79-0 52-11-0-14-23 
Mostly 
antineoplastic CT 51 (100) Ethanol 70% No 5 45 (88) 
Clinical. No systematic 
BC 
2008-Souza 
Dias M.B. et 
al.150 
17 78-22-0 0-0-100-0-0 Mostly antineoplastic CT 17 (100) CEF (ND), AMK (2) or LVX (ND) Yes, 100 ND 14 (82) Undefined 
2008-Broom J. 
et al.103 17 11-89-0 25-21-21-0-33 Antineoplastic CT  17 (100) Ethanol 70% No 5 15 (88) 
Clinical + catheter BC 
negative 1 day after the 
end of ALT 
2009-Del Pozo 
J.L. et al.91 44 100-0-0 100-0-0-0-0 
Antineoplastic CT 
and TPN  44 (100) VAN (2), TEC (10) Yes, 100 10 [10-14] 39 (89) 
Clinical + catheter BC 
negative 7 days after the 
end of ALT 
2009-Del Pozo 
J.L. et al.151 18 100-0-0 5-35-0-0-60 Antineoplastic CT  18 (100) 
VAN (2) +/- GEN (2) (if E. 
faecium), TEC (10), TZP (10), LVX 
(5), TMP/SXT (16/3.2) 
Yes, 100 12 [5-14] 16 (89) 
Clinical + catheter BC 
negative 30 days after the 
end of ALT 
2009-
Rajpurkar M. 
et al.152 
3 66-33-0 40-0-0-0-60 Hemophilia 3 (100) Ethanol 70% No 3 [1-3] 3 (100) 
Clinical + catheter BC 
negative after the end of 
ALT 
2011-McGrath 
E.J. et al.104 80 24-72-4 33-20-9-8-0-30 
Antiinfectious or 
antineoplastic CT, 
TPN  
80 (100) Ethanol 70% No 1 59 (75) 
Clinical + catheter BC 
negative 30 days after the 
beginning of ALT 
2011-
Funalleras G. 
et al.93 
46 28-72-0 0-59-26-0-15 Antineoplastic CT, hemodialysis  46 (100) AMK (2) or CIP (2) Yes, 20 13 [10-16] 44 (96) 
Clinical + catheter BC 
negative 30 days after the 
beginning of ALT 
2011-
Valentine 
K.M. et al.153 
26 15-54-31 14-36-3-11-36 Antineoplastic CT, ICU 26 (100) Ethanol 70% No 1.5 [1-5] 24 (92) 
Clinical + negative 
catheter BC 2 days after 
the beginning of ALT 
2012-Del Pozo 
J.L. et al.94 13 46-54-0 87-0-0-0-13 
Antineoplastic CT, 
hemodialysis  11 (85) 
DAP (5) ¶ 
Yes, 100 if 
TIVAP and 
5000 if 
dialysis 
14 [10-14] 11 (85) 
Clinical + catheter BC 
negative 30 days after the 
end of ALT 
†Expressed as % TIVAP-tunnelled-other.  
‡Expressed as % coagulase-negative staphylococci-Enterobacteriaceae-Pseudomonas spp.-S. aureus-others. 
*Of note, the heparin that is used does not contain antimicrobial preservative. 
§But 3 retreatments needed.  
¶In lactated Ringer's solution providing 45 mg of calcium/L.  
AIDS=acquired immunodeficiency syndrome. ALT=antibiotic lock therapy. AMK=amikacin. BC=blood cultures. CIP=ciprofloxacin. CLI=clindamycin. CT=chemotherapy. DAP=daptomycin. 
ELT=ethanol lock therapy. GEN=gentamicin. ICU=intensive care unit. IMP=imipenem. MIN=minocycline. ND=not determined. NET=netilmicin. PIP=piperacillin. TMP-SMX=trimethoprim-
sulfamethoxazole. TPN=total parenteral nutrition. TZP=piperacillin/tazobactam. 
 
